Does eating oranges reduce inflammatory and other risk markers related to cardiovascular diseases?

Effects of the consumption of oranges on gene expression and other biomarkers of disease and intake in a healthy population in a randomized intervention trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17330010

Enrollment

Registered

2018-08-13

Start date

2015-04-05

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of eating oranges on cardiovascular disease biomarkers in healthy people Circulatory System

Interventions

For the short-term cross-over randomized trial. In a computer generated random order, 15 of the 30 study participants were assigned to the intervention with oranges. 500 g of peeled oranges were admin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy men and women

Exclusion criteria

Exclusion criteria: 1. Diseased 2. Allergic to oranges 3. Immunodeficiency or HIV-positive status 4. Liver cirrhosis or chronic renal failure 5. Serious psychiatric disorders: schizophrenia, bipolar disease, eating disorders, depression, etc 6. Any severe co-morbid condition 7. Alcohol abuse or addition 8. History of major organ transplantation 9. Concurrent therapy with immunosuppressive drugs or cytotoxic agents 10. Current treatment with systemic corticosteroids 11. Current use of weight loss medication 12. Patients with an acute infection or inflammation 13. Any other condition that may interfere with the completion of the study protocol

Design outcomes

Primary

Measure	Time frame
Classical biochemical parameters related to cardiovascular risk at baseline and 4 h/1 month, also including novel omics markers (in plasma and/or urine) analyzed by metabolomics (also including markers of intake), gene expression and other omics	—

Secondary

Measure	Time frame
For the short-term crossover intervention trial, measured at baseline and 4 h: 1. Blood pressure 2. Anthropometric variables (weight, height, waist circumference and body composition by bioimpedance) 3. Genetic polymorphisms 4. Food intake measured by a validated food frequency questionnaire 5. Taste perception tests with standardized tastants for bitter, sour, sweet, umami and salty For the 1-month intervention, measured at baseline and 1 month: 1. Blood pressure 2. Anthropometric variables (weight, height, waist circumference and body composition by bioimpedance) 3. Genetic polymorphisms	—

Measure

Time frame

For the short-term crossover intervention trial, measured at baseline and 4 h: 1. Blood pressure 2. Anthropometric variables (weight, height, waist circumference and body composition by bioimpedance) 3. Genetic polymorphisms 4. Food intake measured by a validated food frequency questionnaire 5. Taste perception tests with standardized tastants for bitter, sour, sweet, umami and salty For the 1-month intervention, measured at baseline and 1 month: 1. Blood pressure 2. Anthropometric variables (weight, height, waist circumference and body composition by bioimpedance) 3. Genetic polymorphisms

—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026